"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"

Recruiting now · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Rheumatoid Arthritis

In brief

The objective of this clinical trial is to determine whether α-tocopherol (vitamin E) supplementation decreases inflammation and clinical activity in patients with rheumatoid arthritis (RA).The main questions to be answered are: * Is supplementation with vitamin E (α-tocopherol) for one month associated with decreased clinical activity and inflammation in patients with RA? Researchers will compare α-tocopherol with a placebo (a look-alike substance containing no active ingredient) to see if α-tocopherol effectively reduces inflammation and clinical activity in patients with rheumatoid arthritis. Participants will: * Take two capsules (one in the morning and one in the afternoon) of either α-tocopherol or placebo every day for a month. * Attend clinic visits at the start of the intervention (baseline) and at the end of the month for final check-ups and tests. * Keep a diary to record your symptoms and how often you take α-tocopherol or placebo.

Key facts

Study ID

NCT06915701

Run by

University of Guadalajara

People needed

46

Starts

2026-02-06

Expected to finish

2027-01-15

Last updated by the study team

2026-02-13

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female sex
• RA classification (ACR/EULAR 2010)
• Early RA 2 years
• Treatment with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations)
• DAS28 ≥3.2
• Vitamin E intake deficiency (<15mg/day)
• No comorbidities
• Age > 18 years
• Voluntary participation and informed consent.

You may not qualify if…

• Liver and kidney disease
• Overlap syndrome
• Coagulation disorders
• Pregnancy
• Consumption of supplements (iron, vitamin E, and K), and medications such as acetylsalicylic acid, amlodipine, estrogen, glucocorticoids and drugs used to treat dyslipidemias in the last three months.
• Elimination Criteria:
• Errors in administration of the 20% supplement
• Adverse effects of the supplement
• Pregnancy during the study
• Insufficient blood sample
• Voluntary withdrawal of informed consent.

Where it is running

• Civil Hospital of Guadalajara — Guadalajara, Jalisco, Mexico (enrolling)
• Universidad de Guadalajara — Guadalajara, Jalisco, Mexico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.